Cipla Ltd and Ranbaxy Laboratories Ltd have been issued preliminary notices, under the Drugs (Price) Control Order 2013, by the government for overcharging consumers for medicines, a government source told Cogencis on Friday. The government has issued 87 such preliminary notices to various drug makers for overcharging, the source added. The new drug pricing policy recommends market-based pricing, allowing manufacturers to sell medicines at an average price of all brands that have more than 1% market share in a segment. The average price would act as a ceiling price for that particular drug.
Help employers find you! Check out all the jobs and post your resume.
